174 related articles for article (PubMed ID: 11342340)
1. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
Vu UE; Pavletic ZS; Wang X; Joshi SS
Leuk Lymphoma; 2000 Nov; 39(5-6):573-82. PubMed ID: 11342340
[TBL] [Abstract][Full Text] [Related]
2. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
Wang P; Pavletic ZS; Joshi SS
Leuk Lymphoma; 2002 Sep; 43(9):1827-35. PubMed ID: 12685840
[TBL] [Abstract][Full Text] [Related]
3. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
4. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
[TBL] [Abstract][Full Text] [Related]
5. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
6. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
7. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
Front Immunol; 2021; 12():619069. PubMed ID: 34108958
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
10. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
König A; Menzel T; Lynen S; Wrazel L; Rosén A; Al-Katib A; Raveche E; Gabrilove JL
Leukemia; 1997 Feb; 11(2):258-65. PubMed ID: 9009090
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Robertson LE; Denny AW; Huh YO; Plunkett W; Keating MJ; Nelson JA
Cancer Chemother Pharmacol; 1996; 37(5):445-50. PubMed ID: 8599867
[TBL] [Abstract][Full Text] [Related]
12. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
13. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
[TBL] [Abstract][Full Text] [Related]
14. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
15. Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis.
Palucka KA; Reizenstein P; Ost A; Porwit-MacDonald A
Leuk Lymphoma; 1998 Feb; 28(5-6):573-81. PubMed ID: 9613988
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
[TBL] [Abstract][Full Text] [Related]
18. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
Morales AA; Olsson A; Celsing F; Osterborg A; Jondal M; Osorio LM
Int J Cancer; 2005 Feb; 113(5):730-7. PubMed ID: 15499630
[TBL] [Abstract][Full Text] [Related]
19. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
